Xiangxue Pharmaceutical (300147) - Total Assets

Latest as of March 2026: CN¥6.66 Billion CNY ≈ $975.13 Million USD

Based on the latest financial reports, Xiangxue Pharmaceutical (300147) holds total assets worth CN¥6.66 Billion CNY (≈ $975.13 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Xiangxue Pharmaceutical to assess how comfortably operating cash covers total debt obligations.

Xiangxue Pharmaceutical - Total Assets Trend (2007–2025)

This chart illustrates how Xiangxue Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Xiangxue Pharmaceutical for net asset value and shareholders' equity analysis.

Xiangxue Pharmaceutical - Asset Composition Analysis

Current Asset Composition (December 2025)

Xiangxue Pharmaceutical's total assets of CN¥6.66 Billion consist of 23.8% current assets and 76.2% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	3.8%
Accounts Receivable	CN¥750.42 Million	11.1%
Inventory	CN¥295.43 Million	4.4%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥979.34 Million	14.5%
Goodwill	CN¥199.72 Million	3.0%

Asset Composition Trend (2007–2025)

This chart illustrates how Xiangxue Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Xiangxue Pharmaceutical.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Xiangxue Pharmaceutical's current assets represent 23.8% of total assets in 2025, an increase from 18.3% in 2007.
Cash Position: Cash and equivalents constituted 3.8% of total assets in 2025, down from 8.0% in 2007.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 8.0% in 2007.
Asset Diversification: The largest asset category is intangible assets at 14.5% of total assets.

Xiangxue Pharmaceutical Competitors by Total Assets

Key competitors of Xiangxue Pharmaceutical based on total assets are shown below.

Company	Country	Total Assets
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Xiamen Amoytop Biotech Co Ltd SHG:688278	China	CN¥3.21 Billion
Syndax Pharmaceuticals Inc NASDAQ:SNDX	USA	$472.67 Million
Neuren Pharmaceuticals Ltd AU:NEU	Australia	AU$331.25 Million
Vor Biopharma Inc NASDAQ:VOR	USA	$506.75 Million
Chengdu Kanghua Biological Products SHE:300841	China	CN¥3.94 Billion
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	China	CN¥1.84 Billion

Xiangxue Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.24	0.28	0.44
Quick Ratio	0.19	0.22	0.30
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥-5.01 Billion	CN¥-4.18 Billion	CN¥-3.38 Billion

Xiangxue Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Xiangxue Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	9.57
Latest Market Cap to Assets Ratio	0.10
Asset Growth Rate (YoY)	-10.0%
Total Assets	CN¥6.75 Billion
Market Capitalization	$653.17 Million USD

Valuation Analysis

Below Book Valuation: The market values Xiangxue Pharmaceutical's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Xiangxue Pharmaceutical's assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Xiangxue Pharmaceutical (2007–2025)

The table below shows the annual total assets of Xiangxue Pharmaceutical from 2007 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥6.75 Billion ≈ $987.02 Million	-10.05%
2024-12-31	CN¥7.50 Billion ≈ $1.10 Billion	-9.45%
2023-12-31	CN¥8.28 Billion ≈ $1.21 Billion	-11.47%
2022-12-31	CN¥9.35 Billion ≈ $1.37 Billion	-17.82%
2021-12-31	CN¥11.38 Billion ≈ $1.67 Billion	+16.39%
2020-12-31	CN¥9.78 Billion ≈ $1.43 Billion	+15.56%
2019-12-31	CN¥8.46 Billion ≈ $1.24 Billion	-1.90%
2018-12-31	CN¥8.63 Billion ≈ $1.26 Billion	-8.63%
2017-12-31	CN¥9.44 Billion ≈ $1.38 Billion	+18.18%
2016-12-31	CN¥7.99 Billion ≈ $1.17 Billion	+71.73%
2015-12-31	CN¥4.65 Billion ≈ $680.73 Million	+29.64%
2014-12-31	CN¥3.59 Billion ≈ $525.08 Million	+3.27%
2013-12-31	CN¥3.47 Billion ≈ $508.46 Million	+17.83%
2012-12-31	CN¥2.95 Billion ≈ $431.54 Million	+53.50%
2011-12-31	CN¥1.92 Billion ≈ $281.12 Million	+4.03%
2010-12-31	CN¥1.85 Billion ≈ $270.22 Million	+164.44%
2009-12-31	CN¥698.31 Million ≈ $102.19 Million	+26.63%
2008-12-31	CN¥551.47 Million ≈ $80.70 Million	-0.35%
2007-12-31	CN¥553.43 Million ≈ $80.98 Million	--

About Xiangxue Pharmaceutical

SHE:300147 China Biotechnology

Market Cap

$653.17 Million

CN¥4.46 Billion CNY

Market Cap Rank

#10765 Global

#2897 in China

Share Price

CN¥6.75

Change (1 day)

-3.30%

52-Week Range

CN¥6.26 - CN¥11.74

All Time High

CN¥25.81